[2020 BIO Asia-Taiwan] Fighting COVID-19, Ever Supreme Bio Technology Can Help!

Date:July 29, 2020

Chinese Version


Ever Supreme Bio Technology is a spin-off company of China Medical University and Healthcare System. It is a new drug development company that provides comprehensive cell therapies, and is committed to the research and development of immune cell and stem cell therapy, the discovery of new treatment opportunities for patients, and to provide personalized precision medicine.

 

To fight against COVID-19, Ever Supreme Bio Technology has developed UMSC01 (Allogeneic umbilical cord mesenchymal stem cells) to treat patients diagnosed with coronavirus. In addition to being approved by the Compassionate Use of Ministry of Health and Welfare, UMSC01 is also approved as a potential drug for the coronavirus by Taiwan Center for Drug Evaluation. Moreover, UMSC01 has applied for the emergency use approval from the US Food and Drug Administration, to perform clinical trials. The performance of Ever Supreme Bio Technology in fighting COVID-19 is well-recognized.

 

Dr. Wen-Liang Huang, the General Manager of Ever Supreme Bio Technology and an expert in chest medicine, introduced, “Mesenchymal stem cells have strong differentiation ability. It can regulate the immune system to inhibit inflammation, generate endogenous repair, and combat the cytokine storm to save the patients’ life. We hope to provide a new opportunity and bring hope to the patients.”

 

Besides fighting COVID-19, Ever Supreme Bio Technology also actively promotes cell therapy due to the increasing number of cancer patients. In accordance with the Special Regulation for Cell Therapy, Ever Supreme Bio Technology not only provides autoimmune dendritic cell therapy, but also received the approval from the Ministry of Health and Welfare to combine dendritic cell (DC) with cytokine-induced killer cells (CIK) into a DC-CIK combined therapy.

 

Ever Supreme Bio Technology has cooperated with 17 medical institutions, and among them, 7 institutions had been approved to receive patients. Currently, there are around 90 cancer patients in these institutions that were benefitted by cell therapy treatment.

 

“In the future, the treatment may be just a cell, not a pill. If UMSC01 can pass the clinical trials and be launched in the market, through the mass production of cell biologics, it can surely benefit more patients,” said Dr. Chu-Chi Liu, the Chairperson of Ever Supreme Bio Technology.


Photos:


	Chairman Chang-Hai Tsai, Superintendent Der-Yang Cho, and Representatives of Ever Supreme Bio Technology

Chairman Chang-Hai Tsai, Superintendent Der-Yang Cho, and Representatives of Ever Supreme Bio Technology

Back